Development of Potent and Selective Inhibitors of Methylenetetrahydrofolate Dehydrogenase 2 for Targeting Acute Myeloid Leukemia: SAR, Structural Insights, and Biological Characterization
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Hsin-Huei Chang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road Zhunan Town, Miaoli County 350, Taiwan, Re…. Hauptthemen laut MEDLINE: Methylenetetrahydrofolate Dehydrogenase (NADP), Leukemia, Myeloid, Acute, Enzyme Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2), a pivotal mitochondrial enzyme in one-carbon metabolism, is significantly upregulated in various cancers but minimally expressed in normal proliferating cells. In contrast, MTHFD1, which performs similar functions, is predominantly expressed in normal cells. Therefore, targeting MTHFD2 with selective inhibitors holds promise for a broader therapeutic window with reduced toxicity and fewer side effects. This study identified selective 2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl ureido-based derivatives through systematic chemical modifications and SAR studies. Structural biology investigations revealed substitutions in the phenyl ring and tail region modulate potency and selectivity toward MTHFD2. Additionally, a comprehensive cell screening platform revealed acute myeloid leukemia cells with FLT3 internal tandem duplication mutations are particularly sensitive to these inhibitors. Furthermore, synergistic effects were observed when combining potential compounds with Alimta. Compound 16e emerged as a leading candidate, demonstrating superior inhibition and selectivity for MTHFD2, favorable pharmacokinetics, and potent antitumor efficacy in MOLM-14 xenograft models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road Zhunan Town, Miaoli County 350, Taiwan, Republic of China.
- Institute of Biotechnology, National Tsing Hua University, Hsinchu 300, Taiwan, Republic of China.
ORCID-Profile: Lung-Chun Lee, Weir-Torn Jiaang, Su-Ying Wu
Förderung
- National Health Research Institutes
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Chang, H. H., Lee, L. C., Hsu, T., Peng, Y. H., Huang, C. H., Yeh, T. K., Lu, C. T., Huang, Z. T., Hsueh, C. C., Kung, F. C., Lin, L. M., Huang, Y. C., Wang, Y. H., Li, L. H., Tang, Y. C., Chang, L., Hsieh, C. C., Jiaang, W. T., Kuo, C. C., & Wu, S. Y. (2024). Development of Potent and Selective Inhibitors of Methylenetetrahydrofolate Dehydrogenase 2 for Targeting Acute Myeloid Leukemia: SAR, Structural Insights, and Biological Characterization. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01775
Vancouver
Chang HH, Lee LC, Hsu T, Peng YH, Huang CH, Yeh TK, et al. Development of Potent and Selective Inhibitors of Methylenetetrahydrofolate Dehydrogenase 2 for Targeting Acute Myeloid Leukemia: SAR, Structural Insights, and Biological Characterization. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01775
BibTeX
@article{Chang2024,
author = {Chang, Hsin-Huei and Lee, Lung-Chun and Hsu, Tsu and Peng, Yi-Hui and Huang, Chih-Hsiang and Yeh, Teng-Kuang and Lu, Cheng-Tai and Huang, Zih-Ting and Hsueh, Ching-Cheng and Kung, Fang-Chun and Lin, Li-Mei and Huang, Yu-Chen and Wang, Yi-Hsin and Li, Li-Hsuan and Tang, Ya-Chu and Chang, Ling and Hsieh, Chih-Chien and Jiaang, Weir-Torn and Kuo, Ching-Chuan and Wu, Su-Ying},
title = {Development of Potent and Selective Inhibitors of Methylenetetrahydrofolate Dehydrogenase 2 for Targeting Acute Myeloid Leukemia: SAR, Structural Insights, and Biological Characterization},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01775}
}
EUVIMED